Drugs / SAR443060
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03757351 | Dec 2018 → Jun 2020 | amyotrophic lateral sclerosis | Sanofi | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-06-09 | Denali Therapeutics Inc. | Results Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi denalitherapeutics.com ↗
Data from the completed Phase 1 study with peripherally-restricted RIPK1 inhibitor DNL758 in healthy volunteer subjects display an encouraging profile, as the molecule appears safe and tolerable at doses tested. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-06-09 | Denali Therapeutics Inc. | Denali Therapeutics Provides Broad Update on Its RIPK1 Program Partnered With Sanofi denalitherapeutics.com ↗ |
| 2019-02-15 | Denali Therapeutics Inc. | Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease denalitherapeutics.com ↗ |
| 2019-01-08 | Denali Therapeutics Inc. | Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS denalitherapeutics.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR443060 | “SAR443060 (previously DNL747) is a selective, orally bioavailable, central nervous system (CNS)-penetrant, small-molecule, reversible inhibitor of RIPK1.” PMID 35649245 ↗ Jun 2022 |
| Known as | DNL747 | “SAR443060 (previously DNL747) is a selective, orally bioavailable, central nervous system (CNS)-penetrant, small-molecule, reversible inhibitor of RIPK1.” PMID 35649245 ↗ Jun 2022 |
| Action | Inhibit | “reversible inhibitor of RIPK1” PMID 35649245 ↗ Jun 2022 |
| Modality | Small molecule | “small-molecule” PMID 35649245 ↗ Jun 2022 |
| Route | Oral | “after oral administration” PMID 35649245 ↗ Jun 2022 |